Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

5 Stocks for Busy Investors: GlaxoSmithKline plc (ADR) (GSK), The Coca-Cola Company (KO)

Page 1 of 2

LONDON — Investing doesn’t have to be a full-time job — or even the thing you’re most passionate about. (Though if it is, we may have a spot for you at The Motley Fool!)

The truth is, you’re busy. You love your money. You’ve worked hard for it and don’t want to watch it idle away in a bank.

But you probably don’t want to obsess about it day in and day out, either.

If this sounds like you, you may be a set-and-forget investor. This means you want to find and own shares in the types of companies that provide a good mix of portfolio stability, peace of mind, and extra income.

Let’s take a closer look.

GlaxoSmithKline PurchaseSize and stability
GlaxoSmithKline plc (ADR)
(LSE:GSK) is a massive, 72 billion pound company with a long tenure in the pharma industry and a strong history of returning cash to shareholders. Though not impossible, wild share price swings in a company like Glaxo are unlikely.

In fact, since July when I first mapped out the five stocks for busy investors, Glaxo has essentially been flat. The FTSE All-Share, by comparison, is up 14% over the same period.

Did I get it wrong?

Not necessarily. Glaxo likely hasn’t caused shareholders many sleepless nights because the share price has been so steady. It also consistently throws off a lot of cash in the form of dividends.

In 2012 alone, GlaxoSmithKline returned 8.8 billion pounds to shareholders through share buybacks and dividends. It currently pays about a 5.1% yield, edging out the pharmaceutical average of 4.8% — and leaving your savings account rate in the dust.

So, what shareholders may have missed in share price appreciation, they’ve made up for — in part — with quarterly dividends of about 17 pence per share.

Consistent and growing cash flows and revenue
Set-and-forget investors can be well served looking for recession-resistant companies for their portfolio. I plucked Unilever plc (ADR) (NYSE:UL), a consumer staples giant with an incredibly steady business, for this very reason. People need the products Unilever sells (think soap, washing-up liquid, margarine, and the list goes on).

Unilever has an established position here in the U.K. as well as a growing presence in emerging markets. With a diverse range of products being sold worldwide, Unilever has a solid, tenured business that puts up consistent cash flows and pays a reliable and well-covered dividend yield (currently about 3.4%).

If you’d set-and-forget this one in July, you’d have seen a nice 18% increase in your shares, plus you’d have received a near-4% dividend paid last October.

Competitive advantage, aka “moat”
When I think about a company with a strong competitive advantage, drinks-maker Diageo plc (ADR) (NYSE:DEO) comes to mind. This company owns a huge range of spirits brands and has a massive distribution network worldwide. It is hard for new entrants to the market to gain ground on — and chip market share away from — Diageo.

Shares in Diageo have lagged the market a bit since my last review in July, posting gains of about 11% against the FTSE All-Share’s 14% advance. Shareholders were, however, sheltered from any wild swings in the share price — and rewarded with a final dividend payment of 27 pence per share in October.

Page 1 of 2
Loading Comments...